Polymyxin B Nonapeptide

Polymyxin B Nonapeptide

SCHEMBL29358904

CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@@H](N)[C@@H](C)O)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC1=O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.77
▸ RCOR1 Q9UKL0 2/20 0.77
▸ SSTR5 P35346 6/20 0.43
▸ SSTR2 P30874 4/20 0.43
▸ SSTR4 P31391 4/20 0.43
▸ KEAP1 Q14145 1/20 0.41
▸ TERF2 Q15554 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ KLK7 P49862 1/20 0.40
▸ LDHB P07195 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Polymyxin B Nonapeptide SCHEMBL25547777 1.00 KDM1A (0.77) KDM1ARCOR1SSTR5SSTR2SSTR4
Polymyxin B Nonapeptide SCHEMBL21498184 1.00 KDM1A (0.77) KDM1ARCOR1SSTR5SSTR2SSTR4
Polymyxin B Nonapeptide SCHEMBL17882149 1.00 KDM1A (0.77) KDM1ARCOR1SSTR5SSTR2SSTR4
Polymyxin B Nonapeptide SCHEMBL20108926 1.00 KDM1A (0.77) KDM1ARCOR1SSTR5SSTR2SSTR4
Polymyxin B Nonapeptide SCHEMBL19386845 1.00 KDM1A (0.77) KDM1ARCOR1SSTR5SSTR2SSTR4
SCHEMBL25547809 0.95 KDM1A (0.71) KDM1ARCOR1SSTR5SSTR2SSTR4
SCHEMBL19545532 0.94 KDM1A (0.70) KDM1ARCOR1SSTR5SSTR2SSTR4
SCHEMBL18165213 0.93 KDM1A (0.73) KDM1ARCOR1SSTR5SSTR2SSTR4
SCHEMBL29360076 0.93 KDM1A (0.73) KDM1ARCOR1SSTR5SSTR2SSTR4
SCHEMBL19532558 0.92 KDM1A (0.76) KDM1ARCOR1SSTR5SSTR2SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12318388-B2 Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling Université de Liège (BE) 2025-06-03 — — US claimed
WO-2024226763-A1 BROAD-SPECTRUM ANTIBIOTIC HYBRIDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT INFECTIONS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-10-31 — — WO claimed
CN-113329753-B Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling 列日大学 2024-08-13 — — CN claimed
EP-3955929-B1 NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING UNIV LIEGE (BE) 2024-05-15 — — EP claimed
CN-114886902-B Application of bardoxolone in preparation of antibacterial drugs 暨南大学 2024-03-29 — — CN claimed
WO-2024003042-A1 NOVEL COMBINATIONS OF SESQUITERPENE ALCOHOLS, POLYMYXINS AND NISIN COMPOUNDS AS ANTIMICOBIAL AND/OR ANTIFUNGAL COMPOUNDS BREAKTHROUGH BIOTECH DRIFT APS (DK) 2024-01-04 — — WO claimed
CN-117138040-A Photosensitizer targeting gram-negative bacteria as well as preparation method and application thereof 上海大学 2023-12-01 — — CN claimed
US-20230380428-A1 BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS SUSTAINABLE COMMUNITY DEV LLC (US) 2023-11-30 — — US claimed
US-20230141981-A1 NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) 2023-05-11 — — US claimed
WO-2023018199-A1 NOVEL ANTIBIOTIC AND USE THEREOF 주식회사 레고켐바이오사이언스 2023-02-16 — — WO claimed
CN-115298198-A Novel compounds and compositions for targeted therapy of kidney-related cancers 上海盟科药业股份有限公司 2022-11-04 — — CN claimed
CN-114886902-A Application of bardoxolone in preparation of antibacterial drugs 暨南大学 2022-08-12 — — CN claimed
WO-2022081174-A1 BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS SUSTAINABLE COMMUNITY DEVELOPMENT, LLC (US) 2022-04-21 — — WO claimed
US-11293024-B2 Antisense antibacterial compounds and methods BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-04-05 — — US claimed
EP-3955929-A1 NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING Université de Liège (BE) 2022-02-23 — — EP claimed
US-20260103491-A1 ARYL SUBSTITUTED POLYMYXIN DERIVATIVES SPERO THERAPEUTICS INC (US) 2026-04-16 — — US disclosed
US-12528837-B2 Aryl substituted polymyxin derivatives SPERO THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
EP-3955929-A1 NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING Université de Liège (BE) 2022-02-23 — — EP disclosed
US-20220040135-A1 THERAPEUTIC COMPOSITIONS OF DECANOIC ACID AND ARGININE WINTERMUTE BIOMEDICAL, INC. 2022-02-10 — — US disclosed
EP-3942038-A1 MODULATORS OF TDP-43 Alteron Therapeutics, Inc. (US) 2022-01-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528837-B2 Aryl substituted polymyxin derivatives PTMS, PNISR, BCAT2 KDM1A 1242/4885RCOR1 3294/4885SSTR5 1737/4885
US-12318388-B2 Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling PIGS, TYMP, TYMS KDM1A 3918/4885RCOR1 4805/4885SSTR5 2803/4885
US-20260103491-A1 ARYL SUBSTITUTED POLYMYXIN DERIVATIVES PTMS, FPR1, BCAT2 KDM1A 1156/4885RCOR1 3053/4885SSTR5 1169/4885
US-11293024-B2 Antisense antibacterial compounds and methods RNGTT, DCLRE1B, POLRMT KDM1A 4714/4885RCOR1 3953/4885SSTR5 3339/4885
US-20230141981-A1 NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS GLS, ATP6V1B1, KRAS KDM1A 3592/4885RCOR1 4682/4885SSTR5 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback